tolvaptan has been researched along with cardiovascular agents in 14 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (cardiovascular agents) | Trials (cardiovascular agents) | Recent Studies (post-2010) (cardiovascular agents) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 17,645 | 1,480 | 6,891 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, KF; Barbagelata, A; Benza, RL; Elkayam, U; Gattis, WA; Ghali, JK; Gheorghiade, M; Klapholz, M; McGrew, FA; O'Connor, CM; Orlandi, C; Ouyang, J | 1 |
| Francis, GS; Tang, WH | 1 |
| Burnett, JC; Cook, T; Gheorghiade, M; Grinfeld, L; Konstam, MA; Maggioni, AP; Orlandi, C; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C | 2 |
| Yancy, CW | 1 |
| Schweiger, TA; Zdanowicz, MM | 1 |
| Cavalcante, JL; Gheorghiade, M; Khan, S | 1 |
| Bahit, MC; Blair, JE; Carson, P; Cook, T; Gheorghiade, M; Haass, M; Hauptman, PJ; Konstam, MA; Metra, M; Miller, AB; O'Connor, CM; Oren, RM; Patten, R; Piña, I; Roth, S; Sackner-Bernstein, JD; Traver, B; Wedge, P | 1 |
| Blair, J; Burnett, JC; Gheorghiade, M; Grinfeld, L; Konstam, MA; Krasa, HB; Maggioni, AP; Ouyang, J; Pang, PS; Swedberg, K; Vaduganathan, M; Zannad, F; Zimmer, C | 1 |
| Tsukada, YT | 1 |
| Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Vaduganathan, M | 1 |
| Ambrosy, AP; Butler, J; Filippatos, G; Gheorghiade, M; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Nodari, S; Subacius, H; Vaduganathan, M | 1 |
| Casscells, SW; Gheorghiade, M; Maggioni, AP; Miller, AB; Pang, PS; Payvar, S; Reid, KJ; Spertus, JA; Swedberg, K; Zannad, F | 1 |
| Maggioni, AP | 1 |
2 review(s) available for tolvaptan and cardiovascular agents
| Article | Year |
|---|---|
Vasopressin-receptor antagonists in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan | 2008 |
The disconnect between phase II and phase III trials of drugs for heart failure.
Topics: Animals; Benzazepines; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Patient Readmission; Patient Selection; Pyridazines; Pyridines; Risk Assessment; Risk Factors; Simendan; Tetrazoles; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2013 |
7 trial(s) available for tolvaptan and cardiovascular agents
| Article | Year |
|---|---|
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Topics: Ambulatory Care; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Diuretics; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Tolvaptan; Ventricular Dysfunction, Left; Weight Loss | 2004 |
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Urea Nitrogen; Body Weight; Cardiovascular Agents; Creatinine; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quality of Life; Sodium; Tolvaptan | 2007 |
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Tolvaptan | 2007 |
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Cause of Death; Female; Heart Failure; Humans; Male; Middle Aged; Patient Readmission; Stroke Volume; Tolvaptan | 2010 |
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hypotension; Male; Middle Aged; Renal Insufficiency; Sodium; Tolvaptan; Treatment Outcome | 2012 |
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Disease Progression; Double-Blind Method; Female; Heart Failure; Hematocrit; Hospitalization; Humans; Kidney Function Tests; Male; Middle Aged; Natriuretic Peptides; Outcome Assessment, Health Care; Prognosis; Renal Insufficiency; Stroke Volume; Survival Analysis; Tolvaptan | 2013 |
Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Temperature; Cardiovascular Agents; Disease Progression; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Risk Assessment; Stroke Volume; Survival Analysis; Tolvaptan | 2013 |
5 other study(ies) available for tolvaptan and cardiovascular agents
| Article | Year |
|---|---|
Vasopressin receptor antagonists: will the "vaptans" fulfill their promise?
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Tolvaptan | 2004 |
Climbing the mountain of acute decompensated heart failure: the EVEREST Trials.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Tolvaptan | 2007 |
EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Europe; Female; Heart Failure; Hospitalization; Humans; Hyponatremia; Male; Middle Aged; North America; Randomized Controlled Trials as Topic; Tolvaptan | 2008 |
[Adverse effects of cardiovascular agents in Japan--update 2012].
Topics: Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Aspirin; Benzazepines; Cardiovascular Agents; Drug Combinations; Embolism; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Hypernatremia; Japan; Platelet Aggregation Inhibitors; Substance Withdrawal Syndrome; Tolvaptan | 2012 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Ethnicity; Europe; Female; Georgia (Republic); Heart Failure; Humans; Internationality; Male; Metoprolol; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Russia; Sample Size; Spironolactone; Ticagrelor; Ticlopidine; Tolvaptan | 2014 |